<i>FCGR2A/CD32A</i>and<i>FCGR3A/CD16A</i>Variants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup - Concepedia

Concepedia

Publication | Open Access

<i>FCGR2A/CD32A</i>and<i>FCGR3A/CD16A</i>Variants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup

DOI Full Paper Access

28

Citations

14

References

2012

Year

Julio Ramírez, J.L. Fernández-Sueiro, Raquel López‐Mejías, Carlos Montilla, Maite Arias, Concepción Moll, M. Alsina, Raimón Sanmartí, Francisco Lozano, Juan D. Cañete

The Journal of Rheumatology

Abstract

Our data indicate that FCGR2A polymorphism may influence the response to TNF-α blockers (namely etanercept) in PsA in a direction opposite to that previously found in patients with rheumatoid arthritis.

References

	Year	Citations

Page 1